试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-08
NSAIDs vs Opioids for Post-op Pain in Supracondylar Humerus Fractures
编号:NCT04905563登记状态:提前终止企业 / 申办者:Le Bonheur Children's Hospital
药物 / 成分:Acetaminophen-Hydrocodone、Acetaminophen and Ibuprofen
登记的停止原因(原文):Clinical evidence supporting the hypothesis of this study has been published
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-08
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
编号:NCT05121948登记状态:提前终止企业 / 申办者:HiberCell, Inc.
药物 / 成分:HC-7366
登记的停止原因(原文):sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Liver Immunosuppression Free Trial
编号:NCT02498977登记状态:提前终止企业 / 申办者:King's College London
药物 / 成分:Biomarker、Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine
登记的停止原因(原文):Primary endpoint not reached.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis
编号:NCT02527421登记状态:提前终止企业 / 申办者:Primus Pharmaceuticals
药物 / 成分:DFD01 Spray
登记的停止原因(原文):Not able to recruit patients with the current enrollment criteria.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
编号:NCT03179605登记状态:提前终止企业 / 申办者:Primus Pharmaceuticals
药物 / 成分:DFD06
登记的停止原因(原文):Difficulty in enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
编号:NCT04144140登记状态:提前终止企业 / 申办者:Eisai Inc.
药物 / 成分:E7766
登记的停止原因(原文):The study was terminated earlier due to a business decision; which was unrelated to safety. In addition, there was no clinical activity data that informed the decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
编号:NCT04352413登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:PLM60
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer
编号:NCT04410874登记状态:提前终止企业 / 申办者:Ivan Litvinov
药物 / 成分:Imvamune
登记的停止原因(原文):Inability to recruit patients/lack of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
编号:NCT04509466登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase、Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase、Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-07
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
编号:NCT04548700登记状态:提前终止企业 / 申办者:CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
药物 / 成分:Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone、Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
登记的停止原因(原文):The sponsor has adjusted its R\&D strategy.
查看官方原始记录 ↗